Focus: Inbrain Neuroelectronics develops neuroelectric therapies using graphene-based cortical interfaces for neurological disorders. The Barcelona-based biotech operates as a pre-revenue clinical-stage company with a focused pipeline in brain-interfacing technology.
Profile data last refreshed 45m ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
5 added, 3 removed. Backfill posture.
Best suited for early-career scientists and engineers willing to trade stability for foundational role-building in a frontier neurotech modality.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Inbrain Neuroelectronics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Inbrain Neuroelectronics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
AstraZeneca warns of the loss of competitiveness of the European pharmaceutical sector - Diari ARA
AstraZeneca warns of the loss of competitiveness of the European pharmaceutical sector Diari ARA
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company